The United States Food and Drug Administration (US FDA) conducted an inspection of the Company’s Unit III, a Formulation manufacturing facility located at Bachupally Village, Medchal Malkajgiri District, Telangana, from July 14 to July 21, 2023, according to Aurobindo Pharma.
The facility has been labeled as ‘Voluntary Action Indicated’ (VAI) in an Establishment Inspection Report that has just been given to the Unit.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
Invest wise with Expert advice
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
